Floatz logo

DEXAMETHASONE

Refractory

UNC Lineberger Comprehensive Cancer CenterSmall moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Refractory cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
The Second Hospital of Shandong University
Phase 2B
Epirubicin
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Pomalidomide
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC
Isatuximab
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 2CCC

View all 33 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →